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Abstract
Introduction: As the immunosuppressive potency of 15-deoxyspergualin (DSG) has been shown in the therapy of
renal transplant rejection and Wegener’s granulomatosis, the intention of this study was to evaluate the safety of
DSG in the therapy of lupus nephritis (LN).
Methods: Patients with histologically proven active LN after prior treatment with at least one immunosuppressant
were treated with 0.5 mg/kg normal body weight/day DSG, injected subcutaneously for 14 days, followed by a
break of one week. These cycles were repeated to a maximum of nine times. Doses of oral corticosteroids were
gradually reduced to 7.5 mg/day or lower by cycle 4. Response was measured according to a predefined decision
pattern. The dose of DSG was adjusted depending on the efficacy and side effects.
Results: A total of 21 patients were included in this phase-I/II study. After the first DSG injection, one patient was
excluded from the study due to renal failure. Five patients dropped out due to adverse events or serious adverse
events including fever, leukopenia, oral candidiasis, herpes zoster or pneumonia. Eleven out of 20 patients achieved
partial (4) or complete responses (7), 8 were judged as treatment failures and 1 patient was not assessable. Twelve
patients completed all nine cycles; in those patients, proteinuria decreased from 5.88 g/day to 3.37 g/day (P =
0.028), Selena-SLEDAI (Safety of Estrogens in Lupus Erythematosus - National Assessment - systemic lupus
erythematosus disease activity index) decreased from 17.6 to 11.7. In 13 out of 20 patients, proteinuria decreased
by at least 50%; in 7 patients to less than 1 g/day.
Conclusions: Although the number of patients was small, we could demonstrate that DSG provides a tolerably
safe treatment for LN. The improvement in proteinuria encourages larger controlled trials.
Trial registration: ClinicalTrials.gov: NCT00709722
Introduction
Systemic lupus erythematosus (SLE) is an aggressive
autoimmune disease. Lupus nephritis (LN) is a major
complication of SLE and a strong determinant of mor-
bidity and mortality. Standard treatment protocols for
lupus nephritis involve intravenous (IV) pulses of corti-
costeroids and cyclophosphamide (CYC) or mycopheno-
late mofetil (MMF) for induction therapy, with oral
corticosteroids (OCS) and azathioprine (AZA) or
mycophenolic acid as long-term maintenance treatment
[1-3]. Although pulsed IV CYC is effective in improving
renal survival, a significant proportion of patients
demonstrate poor renal response or relapses [4,5]. The
optimal therapy for such patients with CYC-resistant or
relapsing LN remains unclear. Moreover, CYC is asso-
ciated with a substantial side-effect profile [6]. The risk
of these side effects remains higher for more than
10 years after termination of CYC treatment, and is
especially high if the patients received a cumulative
dosage of >36 g [7-9].
15-deoxyspergualin (DSG; Gusperimus) shows immu-
nosuppressive activity both in vitro and in vivo, affecting
* Correspondence: hannes.Lorenz@med.uni-heidelberg.de
1Division of Rheumatology, University Hospital Heidelberg, INF410, 69120
Heidelberg, Germany
Full list of author information is available at the end of the article
Lorenz et al. Arthritis Research & Therapy 2011, 13:R36
http://arthritis-research.com/content/13/2/R36
© 2011 Lorenz et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.B-lymphocyte, T-lymphocyte and macrophage/monocyte
function. In rodents and human cell systems, DSG
shows a dose-dependent inhibition of primary and sec-
ondary responses to T-, B- and antigen-presenting cell
dependent reactions [10-19]. It has been demonstrated
that DSG binds with high affinity to heat shock protein
c (hsc) 73 [20,21]. DSG also blocks nuclear translocation
of NF-B in a pre-B-cell line, thereby affecting NF-B-
driven transcription of the kappa light chain [20-23].
Finally, Nishimura et al. [24] reported that DSG inhibits
desoxyhypusine synthase, the first enzyme in the forma-
tion of active eukaryotic translation initiation factor 5A.
This factor is important for the stabilization of certain
mRNA transcripts (TNF-a and others).
The immunosuppressive properties of DSG have been
demonstrated in preclinical animal studies including
SLE models [25-31]. In humans with glucocorticoid-
resistant kidney transplant rejection, DSG shows the
same efficacy rate as the strongly T-cell depleting anti-
CD3 monoclonal antibody [32,33]. DSG has been
licensed in Japan for acute renal allograft rejection since
1994. In 2003, an open clinical trial successfully tested
DSG in patients with persistent ANCA-associated vascu-
litis [34-36]. Adverse events (AE) were common but
rarely led to treatment discontinuation. Against this
background, DSG was granted an orphan drug status
for the treatment of Wegener’sg r a n u l o m a t o s i sb yt h e
European Medicines Agency (EMA).
As DSG induces a reversible maturation block of granu-
locytes, it needs to be administered in cycles with intermit-
tent wash-out periods. In the previous studies, it was
concluded that the degree of the clinical response does
not correlate to the severity or duration of leukopenia eli-
cited in the individual patient. This was an important
influence on the protocol for our current SLE study: for
safety reasons, we shortened the treatment intervals and
started with lower dosages, as SLE patients are more
prone to leuko- and lymphocytopenia than patients with
Wegener’s granulomatosis. In human studies on cancer
treatment, in contrast, DSG was applied intravenously at
much higher dosages and was still generally well tolerated
[37,38]. The study presented here was also encouraged by
beneficial results achieved when three patients with active
LN were treated with DSG using the same protocol as
used here [39]. All three patients had been treated with
various immunosuppressives including cyclophosphamide;
after informed consent, we started treating with DSG
along with corticosteroids, which could be gradually
reduced within the first cycles. Indicators of response were
a decrease of proteinuria, hematuria and an improvement
in the serological parameters of lupus activity [39].
Thus, based on the favourable toxicity profile of DSG,
the limited number of immunosuppressants available for
the treatment of aggressive SLE, the sometimes consid-
erable side effects of cyclophosphamide as the best eval-
uated immunosuppressant for treatment of aggressive
S L E ,t h eg o o de f f i c a c ya n ds a f e t yd a t af o rD S Gi nt h e
treatment of Wegener’s granulomatosis, and the favour-
able data from the three previously mentioned patients
with LN, we initiated this multicenter open phase I/II
trial of DSG in the treatment of refractory LN.
Materials and methods
Study design
The purpose of this open-labeled, multicenter, single
group, dose-finding phase I/II pilot study was to establish
the dose of DSG which reduces LN activity after a mini-
mum of six cycles of treatment without causing World
Health Organization (WHO) grade 3 leukopenia (WBC
<2 × 10
9/L). This was important, as DSG causes reversi-
ble leukocytopenia, lupus patients are prone to leukocy-
topenia as a consequence of the disease itself, and there
is limited data about the long-term treatment of SLE
with DSG. We, therefore, deviated from Wegener’sp r o -
tocol and reduced both the initial dosage and the cycle
duration with DSG. The patients, who had all been pre-
viously treated with standard immunosuppressants, suf-
fered from persistent LN and were on OCS (≤1.0 mg/kg/
day; maximum dose 80 mg/day) at entry into the trial.
The study was in accordance with the ethical standards
of the Helsinki Declaration. The study was registered at
ClinicalTrials (Identifier: NCT00709722).
Endpoints
The response rate as the final outcome of the study was
the primary endpoint. A four-point scale was defined:
complete response (CR), partial response (PR), stable dis-
ease (SD) or treatment failure (TF). The response criteria
were defined prior to the start of the study (Table 1):
for a CR, PR or SD prednisone had to be decreased to
≤7.5 mg/day, a higher dosage was automatically classified
as TF. The presence of urinary erythrocyte or granular
casts excluded CR. As the baseline activity of every
patient is different (renal function, baseline proteinuria),
it was necessary to define baseline proteinuria (g/24 h) or
kidney function (estimated glomerular filtration rate
(EGFR), according to the Cockgroft-Gault formula) as
the reference value for the definition of response for
every patient individually. The baseline was defined as
the renal function and proteinuria level before the onset
of the recent LN flare which qualified the patient for the
study. Response was, therefore, determined as the ratio of
the proteinuria or kidney function at cycle 4, 6 or 9 to the
baseline values of the individual patient. Thus CR, PR, SD
or TF could be determined according to the scheme as
depicted in Table 1. Patients with CR or PR were called
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responders” to DSG.
Secondary endpoints in this study were: incidence of
WHO grade 3 leucopenia and incidence of infections or
other adverse events; responder/non-responder per dosage
of DSG; time and duration of response and Selena-SLE-
DAI (Safety of Estrogens in Lupus Erythematosus -
National Assessment - systemic lupus erythematosus dis-
ease activity index) score during treatment; treatment days
with corticosteroids of ≤7.5 mg/day. An AE was defined as
any adverse deviation from the patient’s baseline condition
during the trial (including laboratory abnormalities, inter-
current diseases and accidents), whether or not the change
was considered to be related to the study drug. As usual,
Table 1 Definition of response criteria
Complete
response
Partial response Stable disease Treatment failure
Criteria Baseline Criteria 1 to 4
must be
fulfilled
Criterion 1 must be
fulfilled, and either 3 or
4, with the other not
downgrading clinical
response to SD or TF
Criterion 1 must be fulfilled,
moreover 3 or 4, with the
other not downgrading clinical
response to TF
If one of criteria 1, 3 or 4
accounts
1. prednisone
equivalent)
< = 7.5 mg/day < = 7.5 mg/day < = 7.5 mg/day ➢ 7.5 mg/day during cycle 4, 6
or 9
2. Urinary
casts
Not detectable Detectable Detectable Detectable
3. Proteinuria A) Normal
(< 0.15 g/day)
< 0.3 g/day > 0.3 g, but a decrease of
> = 25% of the maximum
urinary protein excretion
(measured at entry)
achieved
decrease of <25% of the
maximum urinary protein
excretion (measured at entry)
achieved during DSG treatment,
no further increase of >25% in
the maximum urinary protein
excretion within the previous
two cycles
Within the previous two cycles, a
further increase of >25% in the
maximum urinary protein
excretion
B) Elevated Maximum
increase over
baseline of 25%
If >25% increased
additional urinary protein
excretion
1 was decreased
by at least 25% during
DSG treatment
additional urinary protein
excretion
1 decreased by < 25%
during DSG treatment; no further
increase of >25% in the
maximum urinary protein
excretion within the previous
two cycles
Within the previous two cycles, a
further increase of >25% in the
maximum urinary protein
excretion
C) In case of
chronic
nephrotic
syndrome
Decrease in
proteinuria of
>50%, compared
to the baseline
Decrease in proteinuria of
at least 25%, but less than
50%, compared to the
baseline
Decrease in proteinuria of <25%,
maximal increase of 25%,
compared to the baseline
Further increase in proteinuria of
>25%, compared to the baseline
4. Serum
creatinine and
EGFR
A) Both
normal
Serum creatinine
normal and
impairment of
EGFR
2 improved
by at least 75%
Serum creatinine normal
and impairment of EGFR
2
improved by at least 25%,
but less than 75%
Serum creatinine remained
elevated or impairment of EGFR
2
improved by <25%, but did not
further decrease by >25% within
the previous two cycles
serum creatinine remained
elevated, with a further increase
of >20% over the maximum
serum creatinine occurring
within the previous two cycles
or impairment of EGFR
2 further
increased by >25% within the
last two cycles
B) Decreased
EGFR, normal
serum
creatinine
Serum creatinine
normal and
impairment of
EGFR
2 improved
by >= 75%
Serum creatinine normal
and impairment of EGFR
2
improved by >= 25%, but
<75%
impairment of EGFR
2 improved
by <25% or further decreased to
<= 25% under the minimum
EGFR within the last previous
cycles
EGFR further decreased by >25%
under the minimum EGFR within
the previous two cycles
C) Elevated
serum
creatinine
Maximum
increase 20%
If >20% higher than
baseline serum creatinine,
at least a decrease from
maximum creatinine
during the trial of >15%
Serum creatinine concentration
+/- 15% around the maximum
value observed during the DSG
trial
During the last two cycles,
serum creatinine further
increased by >15% over the
maximum value observed during
the DSG trial
Baseline was defined as proteinuria or renal function (serum creatinine and EGFR) before the current flare of LN. According to these entry parameters, each
patient was attributed to group 3A, 3B or 3C and 4A, 4B or 4C, respectively. Next, the maximal proteinuria or maximal serum creatinine/minimal EGFR during the
current LN flare was determined. Based on these numbers, the additional urinary protein excretion (maximal amount of proteinura - baseline proteinuria) and/or
impairment of renal function (maximal creatinine - baseline creatinine; baseline EGFR - minimum EGFR) could be defined for each patient individually. Response
to DSG at the end of cycle 4, 6 or 9 was then defined in relation to the patient’s individual entry parameters according to the criteria in Table 1.
DSG, deoxyspergualin; EGFR, estimated glomerular filtration rate; SD, stable disease; TF, treatment failure.
1 additional urinary protein excretion: maximal amount of proteinuria (g/day) - baseline proteinuria.
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the clinical investigator at the study center. A serious
adverse event (SAE) was an event which is life-threatening,
results in death, requires or prolongs hospitalization or
results in persistent or significant disability/incapacity.
Reasons for discontinuing treatment with DSG were:
onset of intercurrent diseases which did not allow the
continuation of DSG treatment; common toxicity cri-
teria (CTC) grade 3 suppression of WBC, neutrophils,
hemoglobin, or platelets; withdrawal of consent by the
patient; decision by the physician that discontinuation
was in the best interest of the patient; pregnancy; life-
threatening complications; increase in serum creati-
nine >5 mg/dL; development of cerebral lupus; and
progression of the disease that did not justify the con-
tinuation of DSG therapy (for example, treatment
with OCS (prednisolone equivalent) >1 mg/kg/day or
treatment with CYC required). All patients with pre-
mature termination were included in the safety analy-
sis. If the duration of treatment was at least four
cycles, the efficacy of treatment was assessed, too
(intention-to-treat analysis, ITT). Therapy after the
patient’s withdrawal from the study was left at the
discretion of the investigator.
Patients
Inclusion and exclusion criteria are listed in Table 2.
Conventional immunosuppressants had to have been
stopped at least one week before DSG treatment was
started. Concomitant use of these immunosuppressants
was excluded. Daily OCS doses of 1.0 mg/kg or less
(maximum daily dose 80 mg) were allowed at the start
of DSG therapy. Female patients of child-bearing age
had to use safe methods of contraception. Any other
condition that might have rendered the patient unsuita-
ble for participation in the study was regarded as an
exclusion criterion.
Treatment protocol
Patients were treated for a maximum of nine treatment
cycles with DSG. Treatment was started with a daily
dose of 0.5 mg/kg normal body weight/day, injected s.c.
for 14 days, followed by a break of one week (= one
cycle). OCS dosage was maintained, decreased, or
increased according to the response to DSG.
On the last day of the fourth, sixth and ninth cycle,
the investigator assessed the response using the criteria
specified in Table 1. After cycle 4, the daily dose of
DSG in the subsequent cycles was lowered to 0.35 mg/
Table 2 Inclusions and exclusion criteria
Inclusion criteria Exclusion criteria
Age between 18 and 70 years Chronic infection with HIV, Hepatitis B or Hepatitis C
Diagnosis of SLE according to the ACR criteria Acute severe infection including fungal, viral, bacterial or protozoal
diseases
Signs of active SLE nephritis: increasing urinary protein excretion of 1 g or
more per 24 hours (if initially normal values) or a further increase of >50%
over the baseline proteinuria and/or active urinary sediment and/or
impaired renal function due to SLE nephritis (newly elevated serum
creatinine
Signs of liver toxicity (WHO common toxicity criteria class 2 and higher)
If initially normal values - or >50% increase of serum creatinine levels if
elevated before onset of renal flare), or signs of active LN in renal biopsy
(any renal biopsy in the past two years)
Absence of adequate liver function (total bilirubin >25 μmol/L = 1.4
mg/dL unless otherwise explained (for example, inherited, hemolysis),
ALT or AST >2.5 times upper limit of normal values)
Serum creatinine concentration of μ5.0 mg/dL
Anemia (hemoglobulin <8.0 g/dL)
Prior treatment with one or more immunosuppressive drugs (for example,
CYC, AZA, methotrexate, cyclosporin A, MMF), or plasmapheresis
Leukopenia (leukocytes <4,000/µL unless attributable to SLE: leukocytes
<2,000/µL in these cases)
Initial leukocyte count >4,000 cells/µL (unless leukopenia due to SLE
disease activity: leukocyte count:/2,000/µL
Thrombocytopenia (platelets <50,000/µL),
Written informed consent
Neutrophil counts below 1,000/µL
Hypogammaglobulinemia (IgG below 400 mg/dl)
Pregnancy or lactation
Major and active SLE organ involvement other than the kidney,
especially CNS involvement
History of malignancy
Participation in another clinical trial within six months before screening
2= difference of baseline EGFR minus minimum EGFR during DSG trial from entry.
ACR, American College of Rheumatology; AZA, azathioprin; CYC, cyclophosphamide; LN, lupus nephritis; MMF, mycophenolic acid; SLE, systemic lupus
erythematosus.
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0.7 mg/kg/day, depending on response and/or toxicity.
After cycle 6, the dose was again adjusted according to
response and/or toxicity, to 0.25 mg/kg/day, 0.35 mg/
kg/day, 0.5 mg/kg/day, 0.7 mg/kg/day or 1.0 mg/kg/day.
Corticosteroid therapy
Entry to the study was permitted for patients with doses
of OCS of ≤1.0 mg/kg/day (maximum dose 80 mg/day).
To allow a response to be defined as CR, PR or SD,
OCS dosage had to be gradually reduced down to ≤7.5
mg by Day 1 of cycles 4, 6 or 9. In case OCS dosages
were higher than 7.5 mg/day at Day 1 of cycle 4, 6 or 9,
response was judged as TF (Table 1).
Patient characteristics
In accordance with the entry criteria, all patients in the
ITT and per protocol (PP) population met at least four
of the 11 ACR criteria for the classification of SLE and
suffered from active LN. All patients in the ITT popula-
tion were anti-nuclear antibodies (ANA) positive, most
were dsDNA antibody positive. All patients included
were Caucasian. Three patients were males and 17
patients were females. The mean age was 31.3 years.
Table 3 shows the patients characteristics including age,
time since first diagnosis of SLE, time since first
diagnosis of LN, LN WHO type, pretreatment of LN
within six months before study start.
The diagnosis of LN was confirmed in all patients
included in the ITT and PP population, with a mini-
mum duration of 1.1 year since diagnosis. The mean
duration of SLE was 7.2 years and of LN 6.1 years.
According to 1995 WHO classification criteria, 16
patients suffered from diffuse proliferative nephritis
(type IV) while four patients had a type V (lupus mem-
branous nephropathy); only one patient had a focal pro-
liferative nephritis (type III). Hematuria and proteinuria
was present in all patients.
Most patients had been previously treated with more
than one of the standard medications for LN. The fol-
lowing previous immunosuppressive therapies had
been applied to the patients: predniso(lo)ne (19
patients), azathioprine (10), cyclophosphamide (5),
mycophenolic acid (9), cyclosporine A (3) and rituxi-
mab (1).
All patients had terminated the respective immuno-
suppressive therapy, with the exception of OCS, at least
one week before the start of the treatment with DSG.
All patients had been on these therapies at least three
months before the start of the study.
All co-medication was recorded in the case report forms
(CRFs). Initiation of treatment with angiotensin converting
Table 3 Patient characteristics
CRF
#
Age
(years)
Time since first diagnosis
of SLE
Time since first diagnosis of
nephritis
LN-WHO
type
Pre-treatment of LN within six months before
study start
9 20 1.5 years 1.5 years IV Prednisone, AZA, MMF, HCQ
10 34 2.5 years 2.5 years IV CYC, AZA, Prednisone
11 46 11 years 11 years IV Prednisone, MMF
13 39 8. 5 years 4 years V Prednisone, MMF
14 20 2 years 4 years IV MMF
15 37 7 years 7 years IV CYC, Prednisone, CSA, AZA
16 30 17 years 17 years IV Prednisone,
17 40 21.5 years 21.5 years III AZA, Prednisone, MMF, Immunadsorption
19 20 4.5 years 4.5 years IV AZA, MMF, Prednisone, Methylprednisolon, HCQ,
Rituximab, Octagam
26 35 9 years 8 years IV Prednisone, MMF
31 22, 5 3 years 3 years IV CYC, Prednisone
32 42 12 years 12 years V AZA, Methylprednisolon
33 31 7 years 7 years IV MMF, Prednisone, HCQ
34 19 1 year 1 year IV AZA, CYC, Prednison
35 42 10.5 years 10.5 years IV Prednisone, AZA
36 30 13 years 4 years IV Methylprednisolon AZA
38 22 2.5 years 2.5 years IV CYC, Prednisone, HCQ
39 46 2 years 2 years IV HCQ, plasmapheresis Prednisolone
42 29 10 years 1 year V Prednisone, CSA
49 37, 5 4 years 4 years V Prednisone, CSA
50 20 1 year 1 year IV Prednisone, AZA, MMF, CYC, Prednisone
AZA, azathioprin; CRF, case report form; CSA, cyclosporine A; CYC, cyclophosphamide; HCQ, hydroxychloroquine; LN, lupus nephritis; MMF, mycophenolic acid;
SLE, systemic lupus erythematosus.
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non steroidal antirheumatic drugs was avoided during the
trial as these drugs can improve proteinuria or increase
serum creatinine levels, thereby interfering with response-
defining parameters. For patients chronically treated with
any of these drugs, the medication was continued at the
identical dosage.
The study protocol, including all amendments,
informed consent form and patient information sheet,
was approved by the Ethics Committees before the
start of the study. The study was performed according
to the German Drug Law, the Czech Drug Law and to
the revised version of the Declaration of Helsinki from
1996. Local laboratories were certified and provided
the respective documentation as well as the normal
ranges.
Laboratory tests, statistical analysis
Urine sediment was evaluated in nephrological labora-
tories of the participating centers. Complement levels
were determined turbitimetrically, dsDNA Ab titers by
Farr assay. Statistical analysis was performed with paired
non-parametric Wilcoxon test.
Results
The safety population comprised all 21 patients, the ITT
population 20 patients as one patient dropped out after
the first injection in cycle 1, due to an increase in serum
creatinine (rated as SAE). One patient was taken off the
study after cycle 4, three patients after the fifth cycle,
and four patients after the sixth cycle. Twelve patients
were treated for all nine cycles.
DSG dose remained unchanged in one patient over nine
cycles; in three patients, DSG was reduced to 0.35 mg/kg/
day (all patients were excluded from the study after five to
six cycles). Fifteen patients received 0.7 mg/kg/day of DSG
starting at cycle 5; in five patients DSG could be increased
to 1.0 mg/kg/day in cycles 7 to 9.
Intermittent leukopenia (a known side effect of DSG)
of grade 3 according to WHO classification (< 1.0 to
1.9 × 10
9/L) was observed in seven patients during the
course of the trial; however, it was observed in two
cycles in only one patient. Importantly, neither the
severity of leukopenia nor the DSG dosage correlated to
the frequency and severity of side effects.
Overall, 329 AEs were reported in the 21 patients
(Table 4, 5, 6). The most frequently reported AEs were
infections and infestations (59 reports in 18 patients;
Table 5), followed by gastrointestinal disorders (52
reports in 16 patients) and general disorders/injection
site reaction (39 reports in 17 patients). A total of 218
of 329 AEs were of mild intensity. A relationship with
the administration of DSG was assessed as possible in
86 AEs (18 patients), as probable in 37 AEs (13
patients), and definite in 6 AEs (4 patients). In most of
the AEs (299), the patients remained in the trial. Sixteen
patients received additional therapy due to 81 AEs.
Eight patients experienced 18 SAEs (Table 6), seven
patients were hospitalized and five patients terminated
the study due to SAEs including fever, leukopenia, oral
candidiasis, herpes zoster or pneumonia with a consecu-
tive SLE-flare (Table 6). No deaths occurred during the
study and the follow-up period. Again, DSG dosage and
number or severity of side effects did not correlate.
Table 4 Summary of AEs and their relation to DSG treatment, outcome
Number of AE records Number of patients
nn
Total AE 329 21
Type of AE Infections and infestations 59 18
Gastrointestinal disorders 52 16
General disorders/administration site condition 39 17
Intensity Mild 218 21
Moderate 90 18
Severe 17 7
Outcome Resolved 221 21
Additional therapy 81 16
Hospitalization 14 7
Premature termination 8 5
Relationship to DSG No 156 20
Unlikely 42 15
Possibly 86 18
Probably 37 13
Definitely 6 4
AE, adverse event; DSG, deoxyspergualin.
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(55%) patients achieved PR (four) or CR (seven) on their
final visits (one patient with PR after cycle 5, all other
patients after cycle 9), eight (40%) were judged as TF on
their final visit. Importantly, of these eight patients, two
first responded well and achieved PR or CR, but conse-
quently experienced a flare of their LN. Both patients
had incompliantly stopped application of DSG, thus
they had to be rated as TF. In one patient, response was
not assessable due to missing data. Figure 1 shows the
responses at cycles 4, 6 and 9. Sixteen patients com-
pleted cycle 6 (four in CR, five in PR, four as TF; for
three patients, data were missing for the definition of
response). Twelve patients were treated for the full nine
cycles, with seven patients finishing DSG therapy in CR,
three in PR. Six patients never improved, however, 14 of
20 (70%) patients improved to at least PR at some point
during the study.
Proteinuria decreased significantly: at screening, the
patients in the study population had a mean protein
excretion of 5.124+/-4,379 g/day (range 0.248 to 20.880;
n = 20; missing entry data on proteinuria for one
patient), this decreased to 3.374+/-4,787 g/day in those
12 patients who were treated for all nine cycles. Table 7
summarizes the average proteinuria at entry and at
cycles 4, 6 and 9 for the overall study population. In the
12 patients who were treated through all cycles,
proteinuria fell from 5.883+/-5,503 g/day to 3.374
+/-4,787 g/day (P = 0.028). The increase from cycle 6 to
cycle 9 is mainly due to a 6- to 10-fold increase in pro-
teinuria in the two patients who had incompliantly
stopped application of DSG (patients with CRF 10 and
31 in Table 8). In 13 of 20 patients, proteinuria
decreased by 50% (Table 8); in 7 patients, to less than 1
g/day (levels on entry: 1.13 to 20.88 g/day); and in 9
patients, proteinuria fell below the baseline values before
onset of the recent LN flare. Only one of four patients
with WHO type V LN responded (partially) to DSG; the
patient with WHO type III did not improve.
The analysis of urinary erythrocyte and granular casts
revealed casts at screening and study entry for eight
patients. In all but one patient, casts disappeared at the
latest by cycle 9. At screening, patients of the ITT popu-
lation had a mean EGFR of 83.75 ml/minute (range 34
to 179 ml/minute). By the end of cycle 2, mean EGFR
increased to 91.57 ml/minute. During the subsequent
treatment cycles, EGFR was generally stable with mean
values ranging between 88.45 ml/minute (cycle 5) and
107.81 ml/minute (cycle 9). Due to the high variability
and the low number of patients in this trial this did not
reach statistical significance.
Interestingly, SLE-associated rashes improved in six
out of eight of the affected patients (completely in four
patients, partially in two). Selena-SLEDAI scores were
calculated at entry, on the last day of cycles 4, 6 and 9
and at each follow-up visit. The overall scores decreased
from a mean of 16.9 (12 to 32; n = 20) at screening to
12.9 (4 to 21; n = 20), 13.7 (4 to 22; n = 15) and 11.7 (6
to 21; n = 12) at the end of cycles 4, 6 or 9, respectively
(again, due to the high variability and the low number
of patients in this trial this did not reach statistical sig-
nificance). In the 12 patients who were treated through
all nine cycles, Selena-SLEDAI score decreased from
17.6 at entry to 11.7 at the end of cycle 9. The most fre-
quent parameters scoring for the Selena-SLEDAI at the
end of the study were low complements, positive
dsDNA Ab titers, pyuria, hematuria, rash and arthritis,
T h er e s p o n s ew a sm a i n t a i n e d :a tf o l l o w - u pv i s i t s1 ,2
and 3, the average scores were 11.7 (n = 16), 12.2 (15)
and 12.0 (13), respectively.
Steroid dosage, an indirect measure of treatment effi-
cacy, could be decreased throughout the cycles as
s h o w ni nF i g u r e2 .T h en u m b e ro fd a y so nw h i c ht h e
predniso(lo)ne dose was lower than 7.5 mg/day
increased continuously with treatment cycle, from an
average of 2.8 days during cycle 1 to 18 days during
cycle 9. Complement C3 (screening: 0.70 +/- 0.23 g/L,
cycle 9: 0.76 +/- 0.25 g/L) and C4 (screening: 0.08 +/-
0.05 g/L, cycle 9: 0.15 +/- 0.20 g/L) concentrations
tended to increase, C-reactive protein (CRP) (screening:
4.59 +/- 6.88 g/L; cycle 9: 2.58 +/- 3.21 g/L) and dsDNA
Table 5 Listing of infections and infestations
Infections and infestations Number of AE Number of pat.
Urinary tract infection 12 6
Oral candidiasis 7 6
Vaginal candidiasis 5 4
Nasopharyngitis 5 4
Respiratory tract infection 4 3
Bronchitis 4 2
Pneumonia 3 3
Herpes simplex 3 2
Herpes zoster 3 2
Dental caries 1 1
Fungal skin infection 1 1
Gasteroenteritis 1 1
Infected insect bite 1 1
Labyrinthitis 1 1
Onychomycosis 1 1
Otitis media 1 1
Pharyngitis 1 1
Rhinitis 1 1
Sialoadentitis 1 1
Tinea infection 1 1
Tonsillitis 1 1
Tooth infection 1 1
AE, adverse event.
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Page 7 of 12Table 6 Overview of the SAEs during the study or the post-study observation period
Patient Description of the event No
DSG
cycles
Intensity Relationship to DSG Action taken
A Renal failure (Severe proteinuria) 9 Moderate No (cycle 9, incompliance) Hospitalization
Study termination
Parodontitis, tooth infection, fever Moderate No
B Oral candidiasis 6 Moderate Probably Hospitalization
Fever Moderate Probably Hospitalization
Fever Mild Possibly Study termination
myalgia Mild Unlikely (during follow-up)
Headache Mild Unlikely (during follow-up) Hospitalization
C Angina pectoris 4 Moderate No Hospitalization
Pneumonia Severe Probably Hospitalization
Study termination
D Increase in serum creatinine
(renal failure)
0 Severe No (drop-out after first dose in cycle 1) Additional therapy
Study termination
E Excision of an uterine myoma 9 Not applicable No (during follow-up) Hospitalization
F Leukopenia (two SAEs) 5 Severe Possibly Hospitalization
Study termination
Increased lupus activity with
increased proteinuria and pain
Severe No (during follow-up) Hospitalization
Cyclophosphamide
induced leukopenia
Severe No (during follow-up) Hospitalization
Hospitalization for a
second cyclophosphamide pulse
Not applicable No (during follow-up) Hospitalization
G Herpes zoster 9 Moderate Possibly Hospitalization
Study termination
H Lupus flare (arthritis,
myalgia, skin rash)
9 Moderate Unlikely Hospitalization
DSG, deoxyspergualin; SAE, serious adverse event.
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Figure 1 Response rate during DSG treatment. Response rate (CR in black, PR in dark grey, SD in bright grey, TF in white) at cycles (CYC) 4, 6
and 9 (ITT population). *In both cycles 4 and 6, three patients were not assessable.
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Page 8 of 12antibody levels decreased (screening: 287.6 +/- 277 U/
ml, cycle 9: 160.15 +/- 134 U/ml) (P > 0.05 for CRP and
dsDNA Ab titers).
In the follow-up period after DSG therapy, two
patients (both TF during DSG therapy) received CYC
and four patients received MMF (two patients with CR
during DSG therapy for maintenance, two patients with
TF despite DSG therapy for induction therapy); data on
three of those patients are available and indicate stable
disease. Five patients were treated with rituximab (1 CR,
1 PR, 3 TF during DSG therapy); one of those patients
still flared and three patients experienced a complete
response. Five patients were treated with AZA and
another with Cyclosporine A (CSA) (for maintenance
therapy; all PR or CR with DSG therapy).
Discussion
In this trial, we investigated the safety of DSG in therapy
of lupus nephritis. The trial was encouraged by the ben-
eficial effects observed in three patients with lupus
nephritis who had been treated previously with DSG
[39]. Overall, we included 21 patients; one patient was
excluded after the first injection due to non-drug-related
adverse events. For the ITT population, 20 patients were
evaluable. Furthermore, we chose a regimen which
would facilitate the identification of the appropriate
DSG dosage in SLE. This was especially important as
DSG induces intermittent leucocytopenia, and lupus
patients are prone to leucocytopenia.
Only one patient had decreased leukocyte counts
when entering the study. During treatment with DSG,
this low leukocyte count did not decrease further under
the expected limits during DSG treatment. As expected
by the known side effects of DSG, 13 of the 21 patients
suffered from leucocytopenia at at least one point dur-
ing the treatment period. As in DSG trials in patients
with Wegener’s granulomatosis, the incidence of infec-
tions did not correlate to the degree of leukopenia.
Overall, treatment with DSG as proposed in the study
protocol seems to be reasonably safe. The drop-out rate
is partially explained by the early phase of clinical devel-
opment of DSG, in which one needs to be cautious and
withdraw patients early if there is uncertainty about the
causes of AEs. As seen with other immunosuppressants,
an increased rate of infections needs to be envisioned.
However, it is important to remember that most of the
patients had received other potent immunosuppressants
in their disease history, and it is known that such
patients are particularly prone to infections [40]. The
treatment duration, a maximum of 27 weeks, is too
short to estimate the long-term effects of DSG. Thus,
safety must be considered in the future trials with DSG.
With this proviso, however, DSG seems to be reasonably
well tolerated.
Another aim of the study was to get an idea of the
required dosage of DSG in the treatment of LN. The
Table 7 Proteinuria during DSG treatment: proteinuria (g/day) in the study population (n = patient number)
Patient
number (n)
Proteinuria (study population) P-value compared to entry
Entry 20 5.124 +/- 4,379
cycle 4 20 2.604 +/- 2,580 0.0045
cycle 6 14 2.603 +/- 2,521 0.0392
cycle 9 12 3.374 +/- 4,787 0.028
DSG, deoxyspergualin.
Table 8 Proteinuria over the study period in patients
with a 50% decrease of proteinuria (mg/day)
Patient CRF number Baseline Entry Cycle 4 Cycle 6 Cycle 9
9 2,100 6,800 1,800 n.a. 1,782
10 3,600 20,880 10,710 1,572 15,576
13 2,500 3,022 1,073 2,793
16 360 1,130 1,240 300 230
19 1,000 2,200 1,700 n.a. 1,000
26 120 5,180 800 700
31 1,900 3,920 3,200 1,800 10,800
34 300 3,800 900 1,360 270
35 630 2,000 240 160 480
36 1,680 1,700 770 700 340
39 1,976 n.a. 2,274 2,331 1,058
49 1,700 4,600 2,800 2,900 2,360
50 5,000 11,200 750 2,770 6,401
CRF, case report form.
0
10
20
30
40
50
60
70
Cyc 1 Cyc 2 Cyc 3 Cyc 4 Cyc 5 Cyc 6 Cyc 7 Cyc 8 Cyc 9
m
g
/
d
a
y
Figure 2 Daily OCS dosage over DSG cycles. Each line represents
one patient.
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Page 9 of 12protocol involved treating patients with 0.5 mg/kg/d s.c.
for two weeks, followed by a seven-day break to give the
bone marrow time to compensate for the DSG-related
intermittent leukocyte maturation block. This was an
adaptation of the protocol for the treatment of Wege-
ner’s granulomatosis, in which DSG was injected daily
until leucocyte counts dropped below 4,000 cells/μl. As
SLE patients are prone to leukopenia per se,w e
decreased the starting dosage of DSG to 0.5 mg/kg/d
and limited the injection period of DSG to 14 days.
Thus, therapy was easy to handle without the frequently
required blood count controls. This protocol might,
therefore, offer advantages over the ‘Wegener protocol’,
at least for the initial cycles. In terms of efficacy; how-
ever, the initial dosage of 0.5 mg/kg/d might have been
too low, as for 16 of 20 patients who tolerated the drug,
the dosage subsequently had to be increased to at least
0.7 mg/kg/d. Therefore, in further trials, we recommend
either starting with higher dosages or increasing the
dosage to a 0.7 or 1.0 mg/kg/d (or even higher if
required and tolerated) faster and earlier than after cycle
4 (as in this protocol). We aimed to treat patients for a
maximum of nine cycles (two weeks on drug, one week
off drug = one cycle). Thus, in the best scenario in this
study, patients were treated with DSG (+ low-dose glu-
cocorticoids) for a maximum of 27 weeks. Of the 21
patients, we excluded one patient after the first injec-
tion. Of the remaining 20 patients, 12 were indeed trea-
ted for 27 weeks according to the protocol, with 5
patients reaching the maximal dosage of 1.0 mg/kg/d.
Efficacy was defined according to the response criteria
detailed above and in Table 1. This method of deter-
mining the response in LN allows the improvement to
be assessed individually, as patients differ in their base-
line settings. Based on these parameters, only 4 of the
16 patients completing at least cycle 6 were defined as
TF and taken off the study. Of the 12 patients reaching
cycle 9, 7 finished as CR, 3 as PR, and 2 further patients
reached CR or PR after cycle 6, then experienced a flare
with increasing proteinuria due to incompliance in
cycles 7 to 9 (rated as TF; Table 7). Of course, we can-
not attribute this therapeutic response to DSG alone, as
all patients started with elevated dosages of corticoster-
oids along with DSG. However, 10 out of 21 patients
had been unsuccessfully treated with at least 20 mg/day
of corticosteroids before the start of DSG during this
SLE flare. Nonetheless, the low number of patients and
the lack of a control group with an alternative treatment
strategy prohibit any definite conclusion to be drawn
from this trial on the efficacy of DSG in the treatment
of LN.
Only a controlled randomized trial can help to define
the efficacy of DSG in therapy of LN.
During treatment, renal function was stable in all
patients, despite active LN at inclusion. Interestingly, in
one patient, creatinine concentrations normalized from
values of 1.8 mg/dl at the end of cycle 1, remained nor-
mal throughout the study and again increased during
follow-up. In three patients, renal function was impaired
after termination of DSG-treatment despite treatment
with MMF or CYC, AZA and immunoglobulins,
respectively.
Most patients suffered from WHO type IV nephritis;
only four patients had WHO type V glomerulonephritis
(GN). Proteinuria is one of the best predictors for end
stage renal failure [41]. In 13 patients of the ITT popu-
lation, proteinuria decreased by at least 50% (all WHO
type IV GN), indicating that DSG (in combination with
OCS) seems to affect protein excretion. Remarkably, in
nine patients, proteinuria fell below the baseline values
from before the onset of the recent LN flare. Amongst
patients with WHO type V GN, DSG improved protei-
nuria in one patient only.
The Selena-SLEDAI index as a composite SLE activity
score decreased by four to five points during the trial in
the overall study population, and by almost six points in
the 12 patients who were in the study for the full nine
cycles. This compares to a decrease of 7 points (starting
from the lower level of 12.1) after CYC/rituximab com-
bination therapy [42] or a decrease of 3.6 points after
Rituximab monotherapy [43] in other SLE-studies.
Conclusions
Treatment of LN with DSG (in combination with OCS)
appears to be reasonably safe with tolerable side effects,
but based on the experience with the patients in this
study, the dosing regimen needs to be further optimized.
Moreover, the results of the study encourage the initia-
tion of controlled trials to compare the efficacy of DSG
with established drugs such as MMF, which will answer
the question of the true efficacy of this new drug in
therapy of LN. Finally, due to its special mode of action,
DSG might qualify as a partner for immunosuppressive
combination therapy.
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